Sarepta Therapeutics Inc. (NASDAQ:SRPT) saw an upside of 4.14% to close Tuesday at $95.07 after adding $3.78 on the day. The 5-day average trading volume is 1,271,020 shares of the company’s common stock. It has gained $101.24 in the past week. An average of 1,041,280 shares of the company has been traded in the last 20 days, and the 50-day average volume stands at 861,806.
SRPT’s 1-month performance is 16.17% or $14.60 on its low of $79.95 reached on 09/13/21. The company’s shares have touched a 52-week low of $65.30 and high of $181.83, with the stock’s rally to the 52-week high happening on 01/04/21. YTD, SRPT has lost -44.24% or -$75.42. However, the current price is down -47.71%% from the 52-week high price.
3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
On Mar 10, 217 days have gone by since the last insider trading activity for Sarepta Therapeutics Inc. (SRPT). BEHRENS M KATHLEEN (Director) most recently sold 5,000 shares at $85.76 per share on Mar 10. This transaction cost the insider $428,800. Director, Wigzell Hans Lennart Rudolf, sold 10,000 shares at a price of $83.51 on Mar 08. Then, on Dec 11, Principal Financial Officer Bratica Joseph sold 1,115 shares at a price of $165.00 per share. This transaction amounted to $183,975.
Sarepta Therapeutics Inc. (SRPT) has a trailing price-to-earnings (P/E) ratio of 34.65 for the broader industry and 32.19 for the sector.SRPT stock has a beta of 1.32. Moving on to other valuation ratios, the trailing price-to-sales (P/S) ratio is 12.09 while the price-to-book (PB) in the most recent quarter is 15.64.
Sarepta Therapeutics Inc.’s quick ratio for the period ended June 29 was 4.70, with the current ratio over the same period at 5.30 meaning that SRPT stock is able to fulfill its debt obligations. As well, the company’s long term debt to equity for the quarter ending June 29 was 2.25, while the total debt to equity was 2.25. In terms of profitability, the gross margin trailing 12 months is 86.80%. The trailing 12-month EBITDA margin is -97.08%. The firm’s gross profit as reported stood at $476.72 million against revenue of $540.1 million.
For the quarterly period ending June 29 this year, Sarepta Therapeutics Inc.’s cash and short-term investments amounted to $30.0 million against total debt of $1.18 billion. Net income and sales went up compared to those figures reported in the previous quarter. Analysts expected SRPT to announce -$1.28 per share in earnings in its latest quarter, but it posted -$1.02, representing a 20.30% surprise. EBITDA for the quarter stood at more than -$159.15 million. SRPT stock balance sheet for the quarter ending June 29 shows that total liabilities totaled 2.27 billion, with total debt at $1.18 billion. Shareholders hold equity totaling $79.84 million
Let’s look briefly at Sarepta Therapeutics Inc. (SRPT) price momentum from a technical analysis perspective. The 9-day relative strength index as at close on 12 October was 56.51% to suggest the stock is trending Neutral, with historical volatility in this time period at 68.01%.
The stock’s 5-day moving average is $95.61, reflecting a -0.12% or -$0.11 change from its current price. SRPT is currently trading +18.42% above its 20-day SMA, +18.53% above its 100-day SMA. However, the stock’s current price level is away from the SMA50 and SMA200 by +38.61% and -45.68% respectively.
Stochastic %K and %D was 59.78% and 68.89% and the average true range (ATR) pointed at 4.81. The RSI (14) points at 58.81%, while the 14-day stochastic is at 56.70% with the period’s ATR at 4.30. The stock’s 9-day MACD Oscillator is pointing at 0.10 and 1.73 on the 14-day charts.
In the most recent analyst report for Sarepta Therapeutics Inc. (NASDAQ: SRPT), Guggenheim upgraded it to a Buy rating. They previously had a Neutral rating on the stock. Analysts offering their rating for SRPT stock have a consensus rating for the stock as Overweight. Currently, 0 brokerage advisors rate SRPT as a “sell,”, while 7 advise that investors “Hold.” 0 analysts have rated the stock as underweight. 1 rates the stock as overweight while 13 have offered a “buy” rating.
What is SRPT’s price target for the next 12 months?
Analysts have a consensus price target ranging from a low of $85.00 and a high of $199.00, with their median price target at $118.00. Looking at these predictions, the average price target given by analysts is for Sarepta Therapeutics Inc. (SRPT) stock is $120.61.